Product Spotlight for 10/22/19: Tools for Breast Cancer Research and a New Product

Since October is Breast Cancer Awareness month, we are pleased to focus on some products associated with the study of this disease.  Even occasional readers of the PEPNET newsletter know our commitment to breast cancer research, just due to the frequency of articles we post about the topic. A selection of previous content is also listed below.  One reason: the statistics on breast cancer, while improved, have much room for improvement. It is estimated the impact to women is 2.1 million per year, with 2018 estimates of 627,000 women dying from breast cancer – that is, approximately 15% of all cancer deaths among women. This makes it the most prevalent cancer among women.1

Tinagl1 (Tubulointerstitial nephritis antigen-like 1), has been shown to suppress the TNBC progress and metastasis by binding integrin α5β1, αvβ1, and epidermal growth factor receptor (EGFR), and subsequent contemporaneous inhibition of focal adhesion kinase (FAK) and EGFR signaling pathways.

TINAGL1 Human
PRO-1675

TINAGL1 Human, Sf9
PRO-2422

Read more about Tinagl1 in a past PepTalk, Positive News for Triple Negative.

In breast cancer, pro-inflammatory cytokines, Interleukin 1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α), are released from macrophages and other innate cells which increases the invasive behaviors and metastasis of ERα breast cancer cells.

Interleukin 1 beta (IL-1β)
CYT-208

Tumor Necrosis Factor-alpha (TNF-α)
CYT-223

Learn more in Endocrine Resistance in Breast Cancer Cells.

γ-Glutamylcyclotransferase (GGCT) is found to be over-expressed in numerous cancers. Blocking of GGCT inhibits cancer cell proliferation, therefore a GGCT inhibitor should have anticancer effects. LISA-101 is a stable GGCT fluorogenic substrate and can be used in a cell-based assay using a plate reader. 2

LISA-101
GLU-3234-s

GGCT Human Recombinant
ENZ-062

Additional Products of interest:

Progesterone Receptor Human Recombinant
PRO-535

Gamma-Synuclein Human Recombinant
PRO-395

Myeloid Cell Leukemia Sequence 1 Human Recombinant
PRO-1202

Prolactin Human
CYT-267

Sirtuin-3 Human Recombinant
PRO-462

HER2/ErbB-2 Products

Our previous Breast Cancer Product Spotlights contain additional products not mentioned here,  Research Focus On Breast Cancer and Products for Breast Cancer Research.

We are also pleased to introduce a new host defense peptide, cyclized Tachyplesin III.  Tachyplesin is a type of cationic β-hairpin antimicrobial peptide (AMP) discovered from horseshoe crab hemocytes.  The tachyplesins (I, II, and III) have been found to have hemolytic and antibacterial activity, as well as anticancer effects.  With backbone cyclization, improved stability and reduced toxicity is seen.  They bind best to negatively-charged lipid membranes and work best against Gram-negative bacteria and melanoma cell lines.3

Tachyplesin III
TAC-3046-PI
H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-Tyr-Arg-Lys-Cys-Arg-NH2
(Disulfide bonds between Cys³ and Cys¹⁶/Cys⁷ and Cys¹²)

References:

  1. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
  2. T. Yoshiya, et al., Org. Biomol. Chem., 13, 3182 (2015).
  3. F. Vernon, et al., Int. J. Mol. Sci., 20, 4184 (2019).  doi:10.3390/ijms20174184

Further reading on breast cancer:Stapled in the ER.